HomeHealthcare & Life SciencesPharmaceuticals Hepatic Encephalopathy Treatment Market

Japan Hepatic Encephalopathy Treatment Market Size & Outlook, 2026-2034


Japan Hepatic Encephalopathy Treatment Market Insights

  • As highlighted in Reed Intelligence analysis, the Japan Hepatic Encephalopathy Treatment Market, worth USD 49.48 Million in 2025, is forecasted to achieve USD 102.65 Million by 2034.
  • The Japan market is anticipated to grow at a CAGR of 8.47% during the period 2026–2034.
  • By 2025, Rifaximin represented the largest share of the Drug Class market size.
  • Lactulose is expected to remain the key growth driver within Drug Class, registering the fastest CAGR during the forecast period.

Other Key Findings


  • In 2025, Japan accounted for 2% of the global Hepatic Encephalopathy Treatment Market size.
  • By 2034, United States is expected to lead the global Hepatic Encephalopathy Treatment Market in terms of market size.
  • Within Asia Pacific, China is projected to dominate the regional Hepatic Encephalopathy Treatment Market size by 2034.
  • Japan is identified as the fastest-growing market in Asia Pacific, anticipated to reach USD 102.85 Million by 2034.

Report Summary

Report Scope Details
Base Year for Study 2025
Study Period 2022-2034
Historical Period 2022-2024
Forecast Period 2026-2034
Market Size In 2025 USD 49.48 Million
Market Size In 2034 USD 102.65 Million
Largest segment Rifaximin
Units Revenue in USD Million
CAGR 8.47% (2026-2034)
Segmnetation Covered
Drug Class
  1. Rifaximin
  2. Lactulose
  3. L-ornithine L-aspartate
  4. Antibiotics
  5. Microbiome-based Therapies
Disease Type
  1. Overt Hepatic Encephalopathy
  2. Minimal Hepatic Encephalopathy
Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Related Reports